Vaxcyte, Inc. PCVX Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
As of March 31, 2026 and December 31, 2025, we had investments with a total fair market value of $1.6 billion and $0.3 billion, respectively, in an unrealized loss position, of which $491.9 million and $120.2 million, respectively, were in a continuous unrealized loss position for more than 12 months. As of March 31, 2026, the gross unrealized losses of securities that have been in a continuous unrealized loss position was $4.9 million, of which $4.4 million related to securities that have been in a continuous unrealized loss position for less than 12 months. As of December 31, 2025, the gross unrealized losses of securities that have been in a continuous unrealized loss position was immaterial.
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s cash, cash equivalents, and marketable securities?
- Vaxcyte, Inc. (PCVX) reported cash, cash equivalents, and marketable securities of $1.6B in Q1 2026.
- How has Vaxcyte, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Vaxcyte, Inc.'s cash, cash equivalents, and marketable securities increased by 33.3% year-over-year, from $1.2B to $1.6B.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Vaxcyte, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
